FI3463436T3 - Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää - Google Patents
Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää Download PDFInfo
- Publication number
- FI3463436T3 FI3463436T3 FIEP17729078.0T FI17729078T FI3463436T3 FI 3463436 T3 FI3463436 T3 FI 3463436T3 FI 17729078 T FI17729078 T FI 17729078T FI 3463436 T3 FI3463436 T3 FI 3463436T3
- Authority
- FI
- Finland
- Prior art keywords
- checkpoint inhibitor
- polypeptide
- polypeptides
- mixture
- immune response
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims 31
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims 31
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims 10
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims 10
- 206010028980 Neoplasm Diseases 0.000 title claims 5
- 201000011510 cancer Diseases 0.000 title claims 5
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 239000012634 fragment Substances 0.000 claims 32
- 239000000203 mixture Substances 0.000 claims 32
- 230000028993 immune response Effects 0.000 claims 21
- 230000002163 immunogen Effects 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3463436T3 true FI3463436T3 (fi) | 2023-12-04 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17729078.0T FI3463436T3 (fi) | 2016-06-02 | 2017-06-02 | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4253419A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7321709B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017275782B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3026172A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3463436T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965957T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3463436T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20231650T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE065176T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3463436T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3463436T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3463436T (cg-RX-API-DMAC7.html) |
| RS (1) | RS65007B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3463436T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017207814A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3581649A1 (en) | 2010-02-16 | 2019-12-18 | Ultimovacs ASA | Polypeptides |
| HUE065176T2 (hu) | 2016-06-02 | 2024-05-28 | Ultimovacs Asa | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében |
| GB201803178D0 (en) | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| US12251447B2 (en) | 2018-06-29 | 2025-03-18 | Taiho Pharmaceutical Co., Ltd. | Combined formulation comprising four linked cytotoxic T lymphocyte (CTL) epitopes and a PD-1 pathway inhibitor and methods of use thereof to treat cancer |
| WO2022258794A2 (en) | 2021-06-09 | 2022-12-15 | Ultimovacs Ab | A conjugate |
| WO2024083867A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Biomarker |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL148021A0 (en) | 1999-08-23 | 2002-09-12 | Dana Farber Cancer Inst Inc | Novel b7-4 molecules and uses therefor |
| AU784634B2 (en) | 1999-11-30 | 2006-05-18 | Mayo Foundation For Medical Education And Research | B7-H1, a novel immunoregulatory molecule |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| EP1896582A4 (en) | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| CA2647282A1 (en) | 2006-04-05 | 2007-10-11 | Pfizer Products Inc. | Ctla4 antibody combination therapy |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| TW202442680A (zh) | 2008-12-09 | 2024-11-01 | 美商建南德克公司 | 抗pd-l1抗體及其於增進t細胞功能之用途 |
| EP3581649A1 (en) | 2010-02-16 | 2019-12-18 | Ultimovacs ASA | Polypeptides |
| US9522962B2 (en) | 2010-03-15 | 2016-12-20 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Peptides, conjugates and method for increasing immunogenicity of a vaccine |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| WO2014036562A2 (en) | 2012-08-31 | 2014-03-06 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| SG10201710472PA (en) | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
| EA201992251A1 (ru) | 2013-03-15 | 2020-05-08 | Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания | Противораковые вакцины и способы лечения с их применением |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| JP2017500313A (ja) | 2013-12-09 | 2017-01-05 | ブレット バイオテクノロジー， インコーポレーテッドＢｕｌｌｅｔ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ， Ｉｎｃ． | 特異的ウイルス様粒子−ＣｐＧオリゴヌクレオチドワクチンおよびその使用 |
| CA2934073A1 (en) | 2013-12-20 | 2015-06-25 | The Broad Institute, Inc. | Combination therapy with neoantigen vaccine |
| US9903102B2 (en) | 2013-12-27 | 2018-02-27 | Xiamen Solex High-Tech Industries Co., Ltd. | Concealed embedded component for a waterway system |
| EP3542816A1 (en) | 2014-02-14 | 2019-09-25 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| WO2015128313A1 (en) | 2014-02-25 | 2015-09-03 | Deutsches Krebsforschungszentrum | Rna viruses for immunovirotherapy |
| AU2015259516B2 (en) | 2014-05-13 | 2020-05-28 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and a monoclonal antibody against TIM-3 |
| US20170266270A1 (en) | 2014-05-13 | 2017-09-21 | Bavarian Nordic A/S | Combination Therapy for Treating Cancer with a Poxvirus Expressing a Tumor Antigen and an Antagonist and/or Agonist of an Immune Checkpoint Inhibitor |
| WO2016004213A2 (en) | 2014-07-01 | 2016-01-07 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| EP3166630A4 (en) | 2014-07-07 | 2018-03-28 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016011362A1 (en) | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
| CN106715458A (zh) | 2014-07-18 | 2017-05-24 | 华盛顿大学 | 癌症疫苗组合物及其使用方法 |
| US20170224777A1 (en) | 2014-08-12 | 2017-08-10 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine |
| IL251844B2 (en) | 2014-10-23 | 2024-04-01 | Roussy Inst Gustave | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| CA2954892A1 (en) | 2016-01-19 | 2017-07-19 | Pfizer Inc. | Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens |
| HUE065176T2 (hu) | 2016-06-02 | 2024-05-28 | Ultimovacs Asa | Vakcina kombinációban immunellenõrzõpont inhibitorral felhasználásra rák kezelésében |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7321709B2 (ja) | 2023-08-07 |
| JP2019517508A (ja) | 2019-06-24 |
| WO2017207814A1 (en) | 2017-12-07 |
| ES2965957T3 (es) | 2024-04-17 |
| EP3463436A1 (en) | 2019-04-10 |
| RS65007B1 (sr) | 2024-01-31 |
| EP3463436B1 (en) | 2023-09-20 |
| SI3463436T1 (sl) | 2024-02-29 |
| US11419927B2 (en) | 2022-08-23 |
| JP2022171684A (ja) | 2022-11-11 |
| DK3463436T3 (da) | 2023-12-18 |
| HUE065176T2 (hu) | 2024-05-28 |
| AU2017275782B2 (en) | 2024-08-15 |
| EP4253419A3 (en) | 2024-05-22 |
| LT3463436T (lt) | 2024-01-25 |
| HRP20231650T1 (hr) | 2024-05-10 |
| US12168045B2 (en) | 2024-12-17 |
| CA3026172A1 (en) | 2017-12-07 |
| PL3463436T3 (pl) | 2024-03-04 |
| AU2017275782A1 (en) | 2019-01-24 |
| EP4253419A2 (en) | 2023-10-04 |
| US20230049012A1 (en) | 2023-02-16 |
| PT3463436T (pt) | 2023-12-28 |
| US20190247482A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3463436T3 (fi) | Rokote yhdistelmänä immuunivasteen tarkastuspisteen estäjän kanssa käytettäväksi hoidettaessa syöpää | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| RU2018146886A (ru) | Пути терапевтического применения ингибитора c-raf | |
| EA202190669A1 (ru) | Процесс получения вакцинной композиции | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| BR112019012040A2 (pt) | anticorpo isolado ou fragmento do mesmo, composição, célula isolada, e, métodos para tratamento de câncer, para detecção da expressão de cd73 em uma amostra e para identificação de um paciente com câncer adequado para o tratamento com uma terapia anti-cd73. | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| JP2018501197A5 (cg-RX-API-DMAC7.html) | ||
| CO2018005932A2 (es) | Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas | |
| RU2019106663A (ru) | Комбинированная терапия рака | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| FI3484915T3 (fi) | Uusia zikavirusepitooppeihin spesifisesti sitoutuvia vasta-aineita ja niiden käyttöjä | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| AR111497A1 (es) | Formulaciones de anticuerpos humanos anti-rankl y métodos de uso de estos | |
| JP2019517508A5 (cg-RX-API-DMAC7.html) | ||
| RU2012149227A (ru) | Биологические материалы, относящиеся к her3 | |
| FI3728313T3 (fi) | Syövän yhdistelmähoito IAP-antagonistilla ja anti-PD-1-molekyylillä | |
| BR112020016331A8 (pt) | Métodos para tratar câncer com anticorpos anti-pd-1 | |
| AR103896A1 (es) | Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3 | |
| RU2017136709A (ru) | Комбинированное лечение немелкоклеточного рака легкого с выявленной мутацией в egfr | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии | |
| BR112019011350A2 (pt) | terapia de combinação | |
| AR111380A1 (es) | Tratamiento para el asma con anticuerpo anti-tslp |